This is the authors' abstract. We don't add key points for this paper.
Metallo-β-lactamases (MBLs), such as those encoded by bla IMP-1 , confer resistance to carbapenem antibiotics and represent a critical challenge in treating infections caused by multidrug-resistant Pseudomonas aeruginosa . Here, we report a programmable antimicrobial strategy that restores bacterial antibiotic susceptibility through phage capsid-mediated delivery of CRISPR-Cas13a. We engineered a non-replicative phage capsid, which we called antibacterial capsid (AB-Capsid), packaged with a phagemid encoding a codon-optimized Cas13a from Leptotrichia shahii ( cas13aPA ) and a guide RNA targeting bla IMP-1 . The resulting construct, AB-Capsid_ cas13aPA _ bla IMP-1 , specifically inhibited the growth of bla IMP-1 -expressing P. aeruginosa and significantly reduced the minimum inhibitory concentration (MIC) of imipenem. No bactericidal effect was observed in the absence of the target gene or with a non-targeting AB-Capsid. Furthermore, spacer-dependent and expression-level-dependent killing activity was confirmed using inducible bla IMP-1 systems. These findings demonstrate that programmable AB-Capsids delivering Cas13a provide a gene-specific, non-replicative antimicrobial platform capable of reversing drug resistance and represent a versatile class of CRISPR-based antibiotic adjuvants.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kawaguchi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: